Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Background Cancer is characterized by the rampant proliferation, growth, and infiltration of
malignantly transformed cancer cells past their normal boundaries into adjacent tissues. It is …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

During the course of tumorigenesis and subsequent metastasis, malignant cells gradually
diversify and become more heterogeneous. Consequently, the tumor mass might be …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers,
treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly develo** area …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …

Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …